A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

This study has been completed.
The Hong Kong Society of Nephrology
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
First received: November 21, 2007
Last updated: June 14, 2011
Last verified: June 2011
The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease

Condition Intervention
Chronic Disease
Kidney Diseases
Cardiovascular Diseases
Drug: erythropoietin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients

Resource links provided by NLM:

Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:
  • endothelial function and atherosclerosis [ Time Frame: 6 month, 1 year ]
  • cardiac hypertrophy and cardiac function [ Time Frame: 6 month, 1 year ]

Secondary Outcome Measures:
  • nutrition status [ Time Frame: 6 month, 1 year ]
  • residual renal function [ Time Frame: 6 month, 1 year ]
  • quality of life [ Time Frame: 6 month, 1 year ]

Enrollment: 66
Study Start Date: February 2001
Study Completion Date: November 2003

Ages Eligible for Study:   up to 75 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb
  • Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months
  • Patients below the age of 75

Exclusion Criteria:

  • Patients with valvular heart disease/congenital heart disease
  • Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery
  • Patients with history of heart failure
  • Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months
  • Patients with thalassemic trait or haemoglobinopathies
  • Patients with underlying haematological malignancies
  • Patients with active bleeding
  • Patients with uncorrected iron or other vitamins deficiencies
  • Patients with poor general condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00563355

Prince of Wales Hospital
Hong Kong, China
Sponsors and Collaborators
Hospital Authority, Hong Kong
The Hong Kong Society of Nephrology
Principal Investigator: Angela YM Wang, Dr Department of Medicine & Therapeutics/Nephrology, Prince of Wales Hospital/ The Chinese University of Hong Kong
  More Information

ClinicalTrials.gov Identifier: NCT00563355     History of Changes
Other Study ID Numbers: CRE2000.241  HARECCTR0500004 
Study First Received: November 21, 2007
Last Updated: June 14, 2011
Health Authority: Hong Kong: Ethics Committee

Keywords provided by Hospital Authority, Hong Kong:
chronic kidney disease
cardiovascular disease

Additional relevant MeSH terms:
Cardiovascular Diseases
Chronic Disease
Kidney Diseases
Renal Insufficiency, Chronic
Arterial Occlusive Diseases
Disease Attributes
Pathologic Processes
Renal Insufficiency
Urologic Diseases
Vascular Diseases
Epoetin Alfa

ClinicalTrials.gov processed this record on May 26, 2016